Curated News
By: NewsRamp Editorial Staff
July 27, 2026
Onco-Innovations Advances ONC010 Manufacturing and Partnerships
TLDR
- Onco-Innovations' ONC010 targets DNA repair, offering a potential edge in overcoming cancer treatment resistance.
- Onco-Innovations advanced kilogram-scale manufacturing of a key precursor for ONC010, supporting GMP production and clinical studies.
- Onco-Innovations' ONC010 aims to improve cancer treatment by disrupting DNA repair, potentially saving lives.
- ONC010 is a PNKP inhibitor that disrupts cancer cells' DNA repair, a novel approach to tackle drug resistance.
Impact - Why it Matters
This news matters because Onco-Innovations is progressing a novel cancer therapy that targets DNA repair in cancer cells, potentially offering a new treatment option for resistant tumors. The successful scale-up of manufacturing and strategic partnerships bring ONC010 closer to clinical trials, which could lead to improved outcomes for patients with solid tumors that have limited treatment options.
Summary
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is making significant strides in oncology with its lead candidate ONC010, a PNKP inhibitor designed to disrupt cancer cells' DNA repair mechanisms and overcome treatment resistance. The company recently achieved a milestone by advancing kilogram-scale manufacturing of a key precursor for ONC010's active pharmaceutical ingredient, which will support future formulation development, GMP production, and clinical studies. This progress is part of a broader strategy to build the necessary infrastructure for first-in-human trials.
To accelerate development, Onco-Innovations has signed a letter of intent with Nanosoft Polymers to advance polymer development and drug delivery optimization. Additionally, partnerships with Nucro-Technics and Avance Clinical are supporting bioanalytical development and clinical/regulatory planning. These collaborations underscore the company's commitment to building a robust pipeline and moving ONC010 toward clinical testing. The full article is available at https://ibn.fm/a4ZCj.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, with an exclusive worldwide license to patented technology targeting solid tumors. For more information, visit the company's website at https://oncoinnovations.com/. The latest news and updates are available in the company's newsroom at https://ibn.fm/ONNVF. This content was disseminated by BioMedWire, a specialized communications platform for the biotech and life sciences sectors, powered by IBN.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Onco-Innovations Advances ONC010 Manufacturing and Partnerships
